MENU
Showcases Stock ranks Forex

Allakos Inc (ALLK)
3.9  -0.09 (-2.26%) 08-08 16:00
Open: 4.03 Pre. Close: 3.99
High: 4.08 Low: 3.78
Volume: 616,205 Market Cap: 214M
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 4.083 - 4.104 4.104 - 4.117
Low: 3.733 - 3.759 3.759 - 3.776
Close: 3.862 - 3.902 3.902 - 3.928
Stock Technical Analysis
Overall:     
Target: Six months: 5.20
One year: 6.07
Support: Support1: 3.62
Support2: 3.11
Resistance: Resistance1: 4.45
Resistance2: 5.20
Pivot: 3.64
Moving Averages: MA(5): 3.68
MA(20): 3.63
MA(100): 3.86
MA(250): 36.68
MACD: MACD(12,26): 0.08
Signal(12,26,9): 0.06
%K %D: %K(14,3): 54.98
%D(3): 43.53
RSI: RSI(14): 57.52
52-Week: High: 112.87
Low: 2.54
Change(%): -95.1
Average Vol(K): 3-Month: 959
10-Days: 478
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.

[ ALLK ] has closed below upper band by 30.2%. Bollinger Bands are 6.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Stock chart
Stock News
Sat, 06 Aug 2022
Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash Wisely - Simply Wall St

Thu, 04 Aug 2022
2022-08-04 | NDAQ:ALLK | Press Release | Allakos Inc. - Stockhouse

Mon, 25 Jul 2022
Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors - Yahoo Finance

Wed, 20 Jul 2022
Healthcare Stocks Moving Wednesday: CALA, AVGR, ALLK, PLNHF, ADIL, INZY, REVB, HCSG - InvestorsObserver

Wed, 20 Jul 2022
Allakos (ALLK) Stock: Why It Surged 21.73% Today - Pulse 2.0

Sun, 17 Jul 2022
Allakos Inc. (NASDAQ:ALLK) Receives Consensus Rating of “Hold” from Analysts - Defense World

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 54.78
Shares Float (M) 34.20
% Held by Insiders 6.72
% Held by Institutions 86.36
Shares Short (K) 2680
Shares Short Prior Month (K) 4310
Stock Financials
EPS -7.588
Book Value (p.s.) 4.750
Profit Margin
Operating Margin
Return on Assets (ttm) -50.0
Return on Equity (ttm) -93.9
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -7.438
Qtrly Earnings Growth
Operating Cash Flow (M) -335.88
Levered Free Cash Flow (M) -222.05
Stock Valuation
PE Ratio -0.51
PEG Ratio 0.06
Price to Book value 0.82
Price to Sales
Price to Cash Flow -0.64
Stock Dividends
Dividend
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android